Press Releases
Description text
Loading...
$
(%)
(At Close)
-
SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma
Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in developing -
SL Science Holding Limited Reports Full Year 2025 Financial Results
Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and -
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell -
SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol "SLBT"Transaction provides strategic capital to advance proprietary Gamma delta T cell-based
Loading...